Article Review – Chemoresistance in Pancreatic Cancer

Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors

The authors of this multi-national research demonstrate the important role of “stroma” (tumour surrounding microenvironment) in determining the response of pancreatic cancer to chemotherapy.

They show that some of the cells in the microenvironment (specifically tumour associated macrophages (TAM)) can produce various substances, including insulin-like growth factors (IGFs) which make the cancer cells more resistant to certain chemotherapies.

By blocking these substances, the ability of chemotherapy (gemcitabine) to kill cancer cells is increased.

We have long been aware of the importance of “stroma” in pancreatic cancer, in particular as a result of pioneering work in this area being spearheaded by the likes of Australian researchers such as Professor Minoti Apte, UNSW (The University of New South Wales).

This article highlights the importance of targeting the stroma for the treatment of pancreatic cancer. More research funding is required to further develop these concepts, particularly in Australia, where funding opportunities, particularly in the field of pancreatic cancer have been limited.

You can read the original article here:

Reviewed by Dr Mehrdad Nikfarjam – Liver, Pancreas and Biliary Surgeon